Skip to content

Genmab A/S

GMAB· NasdaqCore metricsCIK 1434265

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -4.01%
Market cap
—
no share count on file
Filings
573
$3.72B
FY 2025+19.2% FY25 yoy
$963.00M
FY 2025−15.0% FY25 yoy
$1.07B
FY 2025+9.6% FY25 yoy
$1.15B
FY 2025derived+4.5% FY25 yoy
$15.37
FY 2025−12.3% FY25 yoy
$1.72B
FY 2025+24.3% FY25 yoy

Price

$51.72+70.64%+$21.41past year
Nov 12, 2026 · IEX last sale
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$3.72BFY 2025
$3.72B0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$3,720,000,000reported
FY 20242024-12-31$3,121,000,000reported
FY 20232023-12-31$2,390,000,000reported

Segments

Geography
Revenue by Geography, FY2023 to FY2025FY2023Denmark · FY2023 · $2.33BJapan · FY2023 · $6.00MUnited States · FY2023 · $55.00MFY2024Denmark · FY2024 · $2.87BJapan · FY2024 · $122.00MUnited States · FY2024 · $131.00MFY2025Denmark · FY2025 · $3.33BJapan · FY2025 · $213.00MUnited States · FY2025 · $180.00MNetherlands · FY2025 · $1.00M
LineFY2025ShareChange
Denmark$3.33B89%+16.0%
Japan$213.00M5.7%+74.6%
United States$180.00M4.8%+37.4%
Netherlands$1.00M0.0%—
China$0.00——
Total$3.72B

From the 20-F filed Feb 17, 2026GMAB

Pharmaceutical preparations

Genmab A/S is the 21st largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Genmab A/S · CIK 1434265 · Engraved from SEC EDGAR